ImmunityBio, Inc. Profile Avatar - Palmy Investing

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulato…

Biotechnology
US, San Diego [HQ]
Strategy & Leadership

Mergers & Acquisitions Beta

M&A Deals · Breakdown

ImmunityBio, Inc. has no acquisition track records yet.

M&A Deals · History

ImmunityBio, Inc. has no acquisition track records yet.

M&A Deals · Within Industry

No current deals within Biotechnology Industry.

M&A Deals · Latest

Act, dont react; Track the most urgent M&A deals across all industries

Details
Owens Corning
Debt
Agg. Maximum Price
$373,155,000.00
Details
?
Equity
Agg. Maximum Price
$n/a
Details
?
Equity
Agg. Maximum Price
$4,221.65
?
Details
?
Equity
Agg. Maximum Price
$2,264,484.00
Details
United Bankshares, Inc.
Equity
Agg. Maximum Price
$206,633,909.86
?
Details
?
Equity
Agg. Maximum Price
$381.73
Details
?
Equity
Agg. Maximum Price
$7,657,428.54
Details
Icahn Enterprises L.P.
Debt
Agg. Maximum Price
$700,000,000.00
?
Details
?
Equity
Agg. Maximum Price
$19,377,844.50
Details
Corebridge Financial, Inc.
Debt
Agg. Maximum Price
$500,000,000.00
End of IBRX's Analysis
CIK: 1326110 CUSIP: 45256X103 ISIN: US45256X1037 LEI: - UEI: -
Secondary Listings
IBRX has no secondary listings inside our databases.